CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 2.93: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
364.74MUSDvs all stocks (USD)
Revenue (TTM)
51.00MUSDvs all stocks (USD)
Profit Margin
-16.42%vs Biotechnology peers
Beta
1.07xvs all stocks
52-Week Change
24.85%vs all stocks
Market Capitalization
364.74MUSDvs all stocks (USD)
Enterprise Value
322.48MUSDvs all stocks (USD)
Forward P/E
11.73xvs Biotechnology peers
Price to Sales (TTM)
7.11xvs Biotechnology peers
Price to Book (MRQ)
9.57xvs Biotechnology peers
Enterprise to Revenue
6.32xvs Biotechnology peers
Enterprise to EBITDA
-58.73xvs Biotechnology peers
Gross Margin
96.23%vs Biotechnology peers
Profit Margin
-16.42%vs Biotechnology peers
Operating Margin
-0.79%vs Biotechnology peers
Return on Assets (TTM)
-5.91%vs Biotechnology peers
Return on Equity (TTM)
-52.68%vs Biotechnology peers
Revenue (TTM)
51.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.69USDUpdated Jul 18, 2026Quarterly Revenue Growth
72.60%vs Biotechnology peers
Gross Profit (TTM)
47.04MUSDvs all stocks (USD)
EBITDA (TTM)
-5.49MUSDvs all stocks (USD)
Net Income (TTM)
-8.38MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
72.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-5.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
44.64MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
3.76MUSDFY2025 · Dec 31, 2025Gross Profit
40.88MUSDFY2025 · Dec 31, 2025Operating Income
-6.35MUSDvs all stocks (USD)
Pre-tax Income
-9.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
106.00KUSDFY2025 · Dec 31, 2025Net Income
-9.74MUSDFY2025 · Dec 31, 2025EBIT
-7.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-5.46MUSDFY2025 · Dec 31, 2025Research & Development
250.00KUSDFY2025 · Dec 31, 2025Selling, General & Administrative
46.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
787.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
28.58MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.58MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.74MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-18.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
36.79MUSDFY2025 · Dec 31, 2025Income Tax Paid
748.00KUSDFY2025 · Dec 31, 2025Interest Paid
4.16MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.74MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
103.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.03MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-2.73MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.44MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.39MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.54MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-19.48MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
20.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
34.54MSharesUpdated Jul 18, 2026Float Shares
16.83MSharesUpdated Jul 18, 2026Shares Short
488.73KSharesUpdated Jul 18, 2026Short Ratio
1.66daysvs all stocks
Short % of Shares Outstanding
1.63%vs all stocks
% Held by Insiders
14.46%vs all stocks
% Held by Institutions
54.29%vs all stocks
Total Cash (MRQ)
40.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.16USDUpdated Jul 18, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
6.98xvs Biotechnology peers
Book Value per Share (MRQ)
1.09USDUpdated Jul 18, 2026Total Assets
70.55MUSDvs all stocks (USD)
Total Current Assets
67.04MUSDFY2025 · Dec 31, 2025Total Liabilities
35.08MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
24.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
36.79MUSDFY2025 · Dec 31, 2025Accounts Receivable
23.22MUSDFY2025 · Dec 31, 2025Inventory
1.56MUSDFY2025 · Dec 31, 2025Accounts Payable
4.63MUSDFY2025 · Dec 31, 2025Deferred Revenue
248.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
189.91MUSDFY2025 · Dec 31, 2025Retained Earnings
-229.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
35.47MUSDvs all stocks (USD)
52-Week Low
5.65USDUpdated Jul 18, 202652-Week High
11.31USDUpdated Jul 18, 202652-Week Change
24.85%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
9.47USDUpdated Jul 18, 2026200-Day MA
8.19USDUpdated Jul 18, 2026Avg 10-Day Volume
166.73KSharesUpdated Jul 18, 2026Avg 30-Day Volume
247.11KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.2900USDUpdated Jul 18, 2026Other Income / Expense
-2.00MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.96Profit Margin: -0.16
Financial Health
Altman Z-Score 2.93: safe zoneNotable
Altman Z-Score: 2.93
High structural barrier to entryNotable
Barrier to Entry: 81.01
Consistent revenue growth patternNotable
Growth Consistency Score: 1.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jamna Auto Industries Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Avalon Technologies Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
The Sherwin-Williams Company
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated